Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

KEYNOTE-361 Investigators

研究成果: Article同行評審

96 引文 斯高帕斯(Scopus)

指紋

深入研究「Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial」主題。共同形成了獨特的指紋。

Medicine & Life Sciences